Felzartamab Durably Reduces Disease-Relevant Biomarkers through Targeting of CD38+ Plasma Cells and Plasmablasts, the Upstream Drivers of IgAN

Authors: Jonathan Barratt, Millie Shah, Lisa Kivman, Tabea Kräft, Julia Rauser, Rainer Boxhammer, Stefan Haertle, Brian M. Schwartz, Paul Manser, Leslie Chinn, Uptal D. Patel, Donna Flesher, Krzysztof Kiryluk

Published: 2024-10-28

DOI: 10.1681/asn.2024ksce36pq

Keywords: No keywords found.

Abstract:
No abstract found.

Source: